JPMorgan Indian loses out as HDFC foreign premium shrinks – JPMorgan Indian Investment Trust says that, for the year ended 30th September 2017, the MSCI India Index (in sterling terms), returned +10.5%. The company produced a return on net assets of +9.0% over the year. However, the return to shareholders was ahead of the benchmark, […]
EP Special Opportunities dives on Luceco profit warning – EP Special Opportunities’ shares are 23.3% lower at lunchtime today (15 December) following a profit warning from its largest investment. Luceco profit warning Luceco made the following announcement this morning “Luceco plc, the manufacturer and distributor of high quality and innovative LED lighting products, wiring accessories […]
Geiger Counter benefits from uranium production cuts – Geiger Counter says that, for the year to 30th September 2017 its net asset value fell by 7.3 per cent which was in line with the fall in the spot uranium price. The share price rose by 15.9 per cent over the year with the discount being 3.3 per […]
F&C Commercial Property buys Bristol office – F&C Commercial Property Holdings Limited, a subsidiary of F&C Commercial Property, has purchased a 56,059 sq ft prime office, One Cathedral Square, in Bristol for GBP33.5 million, reflecting a net initial yield of 5.0 per cent. The property is fully let to the strong covenants of the University of […]
Finsbury Growth outperforms again – Finsbury Growth & Income Trust’s net asset value return per share for the year was 13.7% (2016: 20.6%) and the share price total return was 14.2% (2016: 20.8%). Both outperformed the benchmark, the All-Share Index, measured on a total return basis, which rose by 11.9%. The total dividend for the year […]
Primary Healthcare Properties investing in Cork – Primary Health Properties ICAV, an Irish investment vehicle wholly owned by Primary Healthcare Properties, has agreed to acquire a large modern primary heathcare facility in County Cork, Ireland for a total cost of €20 million. The facility comprises a lettable area of circa 6,500m2 and will be fully let. […]
GCP Infrastructure notes demand for dependable and predictable income – GCP Infrastructure has announced results for the year ended 30 September 2017. The highlights are: Total shareholder return for the year of 2.6% and total return since IPO in 2010 of 97.8% NAV per ordinary share at 30 September 2017 of 110.57 pence (2016: 109.67 […]
3i Infrastructure gets bid for Elenia – In a statement released on 12 December, 3i Infrastructure said “Further to recent speculation, the board of 3i Infrastructure plc confirms that bids have been received from potential acquirers of Elenia. These bids are currently being considered by the company and the other shareholders in Elenia. The company […]
JPMorgan Chinese limiting Tencent and Alibaba exposure – JPMorgan Chinese says that, for the year ended 30 September 2017, the company delivered a return to shareholders of +36.4%. This includes the final dividend of 1.6 pence paid in February 2017. The company’s total return on net assets was +28.5%; this return was just marginally behind the MSCI […]
Baillie Gifford-favourite Alnylam completes key US filing US biotech star and Baillie Gifford stock pick Alnylam Pharmaceuticals has completed its US regulatory application for patisiran, a treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), putting the so-called RNA interference or “gene-silencing” therapeutic on track for approval in mid 2018. Patisiran may become Alnylam’s first […]
UK CAR-T firm Autolus provides update at ASH conference Autolus, which is a closely-watched chimeric antigen receptor T-cell therapy firm backed by three of the UK’s most prominent biotech investors, obtained an important validation of its technology recently with the publication of data on its dual targeting technology at the American Society of Hematology (ASH) conference over […]
Empiric Student Property parts ways with chief executive – the board of Empiric Student Property plc, has announced that Paul Hadaway, the company’s chief executive officer, has received notice to terminate his employment with the Company. Accordingly, Mr Hadaway has ceased to be a director of the company with immediate effect. Tim Attlee, co-founder and chief […]
Local Shopping REIT to continue with piecemeal liquidation – Local Shopping REIT has released results for the year ended 30 September 2017. The highlights are: IFRS Loss for the financial period of GBP0.86m or 1.04 pence per share (2016: Profit GBP0.63m or 0.76 pps). Adjusted operating profit for the period of GBP1.26m or 1.5 pps […]
John Laing Environmental buys Welsh wind farm – John Laing Environmental Assets has announced the acquisition of Llynfi Afan Wind Farm from John Laing Group for a cash consideration, including working capital, of GBP43.0 million. Llynfi Afan Wind Farm is located in the Afan Valley, Abergwynfi, West Glamorgan in Wales and comprises 12 Gamesa 2MW G80 turbines […]
BioPharma Credit acquires royalty interest in diabetes drugs – In its third deal announced in rapid succession, BioPharma Credit has purchased from Royalty Pharma Investments (RPI) a 50% interest in a former Bristol-Myers Squibb-owned royalty stream on two AstraZeneca diabetes drugs. The royalty interested was acquired by RPI from Bristol Myers Squibb on 14 November 2017 and relates to sales of Onglyza […]
Scottish Investment Trust held back by contrarian style this year – Scottish Investment Trust says that, during the 12 months to 31 October 2017, the share price total return was 12.8% and the net asset value per share (NAV) total return (with borrowings at market value) was 11.0%. These returns include a 1.4p uplift from […]
Real Estate Investors sells 24 Bennetts Hill Birmingham – Real Estate Investors has announced the sale of 24 Bennetts Hill, Birmingham for a cash consideration of GBP4.00 million, which is a premium to book valuation and represents a 5.90% net initial yield. The investment property was acquired by the company in December 2014 for GBP2.06 million. […]
Scottish Mortgage to benefit from Denali IPO – Baillie Gifford-managed Scottish Mortgage Investment Trust SMT looks set to receive a significant £85m windfall as a result of last week’s Nasdaq IPO of Denali Therapeutics, a US-based biotech in which it invested in 2016. Baillie Gifford was the lead investors in Denali’s $130m Series B financing round, investing […]
Investment Trust Insider on Blue Prism’s inexorable rise Carthew: the beneficiaries of Blue Prism’s inexorable rise Occasionally, early stage technology companies can produce spectacular share price gains. When this happens, even relatively small investments can make a noticeable difference to a fund’s returns. Regular readers of my column may recall that I wrote about the […]
Gilead reassures with CAR-T therapy durability data – Leading US biotech and investment company favourite Gilead Sciences has reassured investors with an important clinical trial update for its high profile cancer therapy Yescarta, which was obtained via the $12bn purchase of Kite Pharmaceuticals earlier this year. Longer follow-up data from 108 advanced lymphoma patients treated with Yescarta […]
International Public Partnerships buys Frankfurt cop shop – International Public Partnerships Limited has entered into a binding commitment to acquire a stake in the new public private partnership police centre of South-East Hesse in Offenbach. International Public Partnerships has committed to invest c.EUR8 million for a 45% shareholding in the project. The project has been […]
Edinburgh Worldwide gets new deputy managers – Following discussion between the board and managers, Edinburgh Worldwide has announced the appointment of Svetlana Viteva and Luke Ward as deputy portfolio managers with immediate effect. Svetlana and Luke are part of Baillie Gifford’s Global Discovery investment team which is headed by Douglas Brodie, the manager of Edinburgh Worldwide. This […]
Isaly steps down from OrbiMed and Worldwide Healthcare Trust Veteran US biotech analyst and OrbiMed Capital founder Samuel Isaly has stepped down from his role as Managing Partner and separately as a director of UK-listed Worldwide Healthcare Trust WWH, which is managed by OrbiMed alongside Biotech Growth Trust BIOG. Isaly will be replaced at the New […]
JPMorgan Elect will introduce borrowings in income pool – JPMorgan Elect has published its annual report covering the year ended 31 August 2017. The Managed Growth portfolio delivered a total return on net assets of 20.2%, compared with the portfolio’s benchmark which returned 16.7%. The share price total return was 19.6%. For the year ended 31st […]
Gilead acquires Cell Design Labs to bolster CAR-T presence Leading US biotech Gilead Sciences is to acquire privately-held Cell Design Labs in a structured buy out valued at to $567m, including the 12.2% shareholding it already holds as a result of its $12bn acquisition of Kite Pharmaceuticals earlier this year. The Kite deal propelled Gilead […]
Alexion stock rises on reports of activist investor – Stock in the US rare disease specialist Alexion Pharmaceuticals is up 6% this morning on reports that the famed New York-based activist hedge fund Elliot Management has taken a stake. Elliott has reportedly threatened to initiate a proxy battle potentially to replace the relatively new management team […]
Baring Emerging Europe outperforms as Polish stocks soar – For the year ended 30 September 2017, Baring Emerging Europe returned 26.9% in NAV terms and 27.6% in share price terms against a 21.4% return for its benchmark, the MSCI Emerging Markets Europe 10/40 Index. The dividend has been increased from 23p to 32p. The manager […]
FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]
Electra underperforms as it shrinks – Electra Private Equity reports that, for the year ended 30 September 2017, its NAV total return was 9%, well behind that of the Mid 250 Index at 14%. Including their third special dividend announced 23 October 2017, they have returned GBP1.8bn to shareholders since 1 October 2016. The shareholder return was […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated